Androgen biosynthesis Pathway R-HSA-193048

Androgen biosynthesis is the metabolic pathway that generates male sex steroids from cholesterol. In humans, this process occurs mainly in the adrenal cortex, testes and ovaries, and involves a series of enzymatic reactions that convert pregnenolone and progesterone into dehydroepiandrosterone, androstenedione, testosterone and dihydrotestosterone (DHT). The pathway is critical for male sexual development, reproductive function and anabolic processes, and its dysregulation underlies a spectrum of endocrine disorders. For researchers, the androgen biosynthesis pathway (Reactome R-HSA-193048) offers a tractable system to study steroidogenic enzyme function, substrate channeling and endocrine feedback. The pathway includes cytochrome P450 enzymes such as CYP17A1, short-chain dehydrogenases/reductases (HSD3B1, HSD3B2, HSD17B3, HSD17B12) and 5-alpha reductases (SRD5A1, SRD5A2, SRD5A3). These enzymes are targets for drugs like finasteride and dutasteride, and their mutations cause disorders of sex development. Understanding androgen biosynthesis is also clinically relevant because androgen excess is a hallmark of polycystic ovary syndrome (PCOS), idiopathic hirsutism and androgen-secreting adrenal tumors. Moreover, the pathway intersects with adrenal and gonadal steroidogenesis, making it a focal point for studies on adrenal cancer, metabolic syndrome and reproductive endocrinology. What Is the Androgen biosynthesis Pathway? The androgen biosynthesis pathway (Reactome R-HSA-193048) describes the biochemical steps that transform cholesterol-derived pregnenolone and progesterone into active androgens. It begins with the conversion of pregnenolone to 17-hydroxypregnenolone by CYP17A1, followed by cleavage to dehydroepiandrosterone (DHEA) via the 17,20-lyase activity of CYP17A1. DHEA is then converted to androstenedione by HSD3B1/2, and androstenedione is reduced to testosterone by HSD17B3 (in testes) or HSD17B12 (in other tissues). Testosterone can be further converted to the more potent dihydrotestosterone (DHT) by SRD5A1, SRD5A2 or SRD5A3. The pathway also includes alternative or backdoor routes that bypass conventional intermediates, contributing to androgen production in specific physiological and pathological contexts.

The androgen biosynthesis pathway (Reactome R-HSA-193048) describes the biochemical steps that transform cholesterol-derived pregnenolone and progesterone into active androgens. It begins with the conversion of pregnenolone to 17-hydroxypregnenolone by CYP17A1, followed by cleavage to dehydroepiandrosterone (DHEA) via the 17,20-lyase activity of CYP17A1. DHEA is then converted to androstenedione by HSD3B1/2, and androstenedione is reduced to testosterone by HSD17B3 (in testes) or HSD17B12 (in other tissues). Testosterone can be further converted to the more potent dihydrotestosterone (DHT) by SRD5A1, SRD5A2 or SRD5A3. The pathway also includes alternative or backdoor routes that bypass conventional intermediates, contributing to androgen production in specific physiological and pathological contexts.

Androgen biosynthesis is fundamental to male sexual differentiation, reproductive health and anabolic balance, and its dysregulation is implicated in common endocrine disorders such as PCOS, hirsutism and adrenal tumors. The pathway also provides validated drug targets: 5-alpha reductase inhibitors (finasteride, dutasteride) are used to treat benign prostatic hyperplasia and androgenetic alopecia by blocking DHT synthesis. Additionally, rare mutations in pathway enzymes cause disorders of sex development, making this pathway a model for genotype-phenotype correlations in steroidogenesis.

The following genes encode enzymes, cofactors and regulatory subunits that participate in androgen biosynthesis (Reactome R-HSA-193048).

Androgen biosynthesis is regulated by the hypothalamic-pituitary-gonadal (HPG) axis: luteinizing hormone (LH) from the pituitary stimulates testicular Leydig cells to produce testosterone, while adrenocorticotropic hormone (ACTH) drives adrenal androgen production. Negative feedback by testosterone and DHT suppresses gonadotropin-releasing hormone (GnRH) and LH secretion. In the adrenal cortex, ACTH from POMC-derived peptides upregulates CYP17A1 and HSD3B2 expression. Additionally, local factors such as insulin-like growth factor 1 (IGF-1) and insulin can enhance ovarian androgen synthesis, contributing to PCOS. Pharmacological inhibitors like finasteride and dutasteride block SRD5A enzymes, reducing DHT levels and providing a means to probe pathway flux.

Androgen excess is a cardinal feature of polycystic ovary syndrome (PCOS) and idiopathic hirsutism, leading to clinical manifestations such as hirsutism, acne and ovulatory dysfunction. Elevated ovarian and adrenal androgen production, often driven by insulin resistance and LH hypersecretion, contributes to the phenotype. The Ferriman-Gallwey score is widely used to quantify hirsutism in clinical research. Targeting androgen biosynthesis enzymes, such as CYP17A1, is a therapeutic strategy for severe hyperandrogenism.

Adrenal tumors can autonomously secrete androgens, causing virilization and sometimes Cushing syndrome. These tumors often overexpress CYP17A1 and HSD3B2, leading to excessive DHEA and androstenedione production. Diagnosis relies on elevated serum DHEA-S and testosterone, and treatment is surgical resection. Research models using adrenal cancer cell lines help dissect the molecular drivers of androgen overproduction.

Inactivating mutations in HSD17B3, SRD5A2 or CYP17A1 cause 46,XY DSD with undervirilization, ambiguous genitalia or complete female external genitalia at birth. These conditions highlight the critical role of androgen biosynthesis in male sexual differentiation. Genetic diagnosis and functional studies of mutant enzymes are essential for understanding genotype-phenotype relationships.

In congenital adrenal hyperplasia due to 21-hydroxylase deficiency, excess 17-hydroxyprogesterone can be shunted into the backdoor pathway, producing DHT and causing virilization of female fetuses. This alternative route involves SRD5A1 and AKR1C enzymes and operates independently of testosterone. Studying this pathway may reveal new therapeutic targets for preventing prenatal virilization.

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold standard for quantifying androgens such as testosterone, DHT and androstenedione in cell culture media or serum. This method enables precise measurement of pathway flux and is essential for validating CRISPR models of androgen biosynthesis.

RNA sequencing can quantify expression of all genes in the androgen biosynthesis pathway (CYP17A1, HSD3B1/2, HSD17B3, SRD5A1/2/3) under different conditions. It is useful for identifying compensatory changes after gene knockout or in disease states like PCOS.

Androgen receptor (AR) reporter assays measure the functional output of androgen synthesis by detecting AR-driven luciferase expression. These assays are used to assess the potency of synthesized androgens and the efficacy of inhibitors like finasteride.

Enzyme-linked immunosorbent assays (ELISA) and Western blotting can detect steroidogenic enzymes and hormones in cell lysates or media. These methods complement mass spectrometry and provide protein-level validation of CRISPR edits.

EDITGENE provides advanced CRISPR gene editing services to accelerate research on the androgen biosynthesis pathway (R-HSA-193048). By combining knockout, point-mutation, knock-in and overexpression technologies with functional validation, EDITGENE enables precise dissection of steroidogenic enzyme function and disease mechanisms.

The androgen biosynthesis pathway (R-HSA-193048) is a central metabolic cascade in human endocrinology, with profound implications for sexual development, reproductive health and diseases such as PCOS, adrenal tumors and DSD. Its enzymatic steps are well-defined and druggable, making it a fertile ground for both basic and translational research. CRISPR-based models now allow researchers to dissect each gene's contribution to androgen production with unprecedented precision. By leveraging knockout, point-mutation, knock-in and overexpression strategies, scientists can uncover new therapeutic targets and biomarkers for androgen-related disorders.